Stockreport

iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506

Precision BioSciences, Inc.  (DTIL) 
Last precision biosciences, inc. earnings: 11/12 07:15 am Check Earnings Report
PDF ECUR-506 is an investigational gene editing-based therapy for the treatment of Ornithine Transcarbamylase (OTC) deficiency PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc. [Read more]